VCYT Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Veracyte (NASDAQ: VCYT)
›
Veracyte (NASDAQ: VCYT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 755 employees.
The shares were at 25.04 USD on 19 November 2026, down 45.6% over 52 weeks. Its 52-week range is 21.91 USD to 60.91 USD: the price is 58.9% below the high and 14.3% above the low.
At a market capitalisation of 2.02B USD, it trades at 16.3 times trailing earnings and 16.1 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, a discount of 55% for VCYT.
Veracyte reports return on equity of 5.1%, an operating margin of 15.0% and revenue up 15.1% year over year.
It holds more cash than debt, a net cash position of 329.80M USD. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 10 analysts cover the stock, with an average rating of Buy; their mean price target of 41.60 USD is 66.1% above the current price. The next earnings report is expected on 24 February 2027.